Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multi-center, Double-blind Randomized Controlled Clinical Trial on the Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass Opacities

NCT04982900 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT04982900
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04982900 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multi-center, Double-blind Randomized Controlled Clinical Trial on the Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass Opacities
Lead sponsor
Ruijin Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
October 1, 2021
Completion date
August 1, 2022
Enrollment
138 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

multiple primary lung cancers